8.800USD+0.23%Mkt Cap: 626.47M USDP/E: —Last update: 2026-05-26
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap626.47M USD
Enterprise Value382.21M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.44M USD
Revenue/Share—
Last Price8.800 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.17
PEG—
EV/EBITDA-10.68
EV/Revenue—
P/S—
P/B5.45
EPS (TTM)-0.92
EPS (Forward)-0.71
52W Range
1.87071% of range11.61
52W High11.61 USD
52W Low1.870 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-31.39%
ROA-28.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.93M USD
CapEx (TTM)732.92K USD
FCF Margin—
FCF Yield-3.20%
Net Debt-89.54M USD
Net Debt/EBITDA2.50
Balance Sheet
Debt/Equity0.01
Current Ratio8.76
Quick Ratio8.59
Book Value/Sh1.591 USD
Cash/Share1.665 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)17.56 USD
Target Range14.80 USD – 23.00 USD
# Analysts5
Ownership
Shares Out.54.41M
Float40.34M
Insiders22.44%
Institutions49.91%
Short Interest
Short Ratio4.4d
Short % Float7.17%
Short % Out.5.55%
Shares Short3.02M
Short (prev mo.)3.12M
Technical
SMA 509.483 (-7.2%)
SMA 2005.699 (+54.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.01M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—